Brigham Young University

The Scripps Research Institute

The University of Chicago

Nextek Power Systems, Inc.

Sandia Corporation

Other

National Jewish Medical and Research Center

University of Utah Research Foundation

Vanderbilt University

Paul B Savage

Carl A Genberg

Luc Teyton

Albert Bendelac

Chad S Beus

Chunhong Li

Michael Hibbs

Howland D T Jones

Susan J Altman

Carl Genberg

Ronald L Bracken

Paul Wickett

Alex M Adelson

Donald Y Leung

Jared Lynn Randall

Michael C Moore

Andrew S Thompson

Ross A Miller

Dustin Williams

Roy Drake Bloebaum

William George Wilhelm

Derya Unutmaz

Benjamin J Darien

Kristofer D Sinclair

Michael D Triplett

Ben Hartman

Thomas Elliott Jacks

Dapeng Zhou

Bryan S Haymond

Jeffrey Hunsinger

Saurabh Shashikant Chitre

Thomas Elliot Jacks

Kunal Arvind Varia

Ross Allen Miller

Andrew Steven Thompson

Cationic steroidal antimicrobial (CSA) compounds having a structure of Formula I, II or III, or salt thereof, wherein at least one of R-R, (e.g., R) includes a terpenyl group attached via an ester or amide linkage and at least one R-R, (e.g., R, Rand R) is an amino acid linked to the steroidal backbone by an ester or amide linkage:

Cationic steroidal antimicrobial compounds with endogenous groups

The present disclosure describes compositions and methods for regenerating tissue and/or preventing tissue loss by stimulating stem cells. A method includes providing a treatment composition including one or more CSA compounds and a carrier, applying the treatment composition to a targeted tissue region of a subject, and the treatment composition stimulating tissue regeneration and/or preventing tissue degradation at the targeted region of the subject.

Use of CSA compounds to stimulate stem cells and hair growth

The present disclosure describes compositions and methods for deactivating coronavirus. A method includes providing a deactivation composition including one or more CSA compounds and a carrier, administering the deactivation composition to a subject, and the deactivation composition deactivating coronavirus virions in the subject or coming into contact with the subject. The method can thereby prevent, decrease, or inhibit a coronavirus infection, such as COVID-19, of the subject.

Use of cationic steroidal antimicrobial compounds to deactivate coronavirus

The present disclosure describes treatment compositions and methods for preventing and/or treating microbial infections of ciliated tissues, such as tissues of the trachea, lungs, and sinuses. The method utilizes a treatment composition that includes a cationic steroidal antimicrobial (CSA) compound, a poloxamer, and a carrier, which is administered to ciliated tissue, such as lung tissue, in order to prevent or treat a microbial infection by killing microbes associated with the ciliated tissue. The poloxamer forms micelles that encapsulate the CSA compound, the poloxamer being included in the treatment composition in an amount, by weight, that is about 100 to 1000 times the amount of the CSA compound.

Method of treating ciliated tissue using CSA micelles

Cationic steroidal antimicrobial (CSA) compounds having a structure of Formula I, II or III, or salt thereof, wherein at least one of at least one of R-R, (e.g., R, Rand R) is linked to the steroidal backbone by a urethane group: At least one of R-R, (e.g., R, Rand R) has the following urethanyl structure:—O—(C═O)—NRRwhere Rand Rare independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aminoalkyl, aminoalkenyl, aminoalkynyl, or aminoaryl, provided that at least one of Ror Rincludes an amino group (e.g., Ris hydrogen and Ris (C-C)aminoalkyl). Rcan have the following structure:—R—(C═O)—NRRwhere Ris omitted or alkyl, alkenyl, alkynyl, or aryl, and Rand Rare hydrogen, alkyl, alkenyl, alkynyl, or aryl, provided that at least one of Ror Ris not hydrogen.

Cationic steroidal antimicrobial compounds with urethane linkages

Compositions and methods for treating, reducing, or preventing a disease or symptom such as gingivitis, periodontitis, gastritis, colitis, ileitis, Crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, ulcerative colitis, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer, a gastrointestinal ulcer, an autoimmune disorder, or pain. The method includes identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.

Methods for treating inflammation, autoimmune disorders and pain

Methods of treating, reducing, or preventing lung infections or lung inflammation include identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Treatment of cystic fibrosis lung infections, COPD lung infections, inflammation of the lungs in these patient populations, and lung scarring in these patient populations is also described.

Methods for treating lung infections and inflammation

Disclosed herein are methods of treating, reducing, or preventing a disease such as oral mucositis, gastric mucositis, or inflammatory fibrosis, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.

Disclosed herein are cationic steroidal antimicrobials ('CSA compounds' or 'ceragenins') and methods of making the same. Particularly advantageous methods are identified for the synthesis of CSA compounds. CSA compounds may be formulated for treating subjects with ailments responsive to CSA compounds, including but not limited to treating bacterial infections. Accordingly, some embodiments include formulations and methods of administering CSA compounds.

Cationic steroidal antimicrobials

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.

Cationic steroidal antibiotic compositions for the treatment of dermal tissue

This disclosure relates to sporicidal compositions and uses thereof. The sporicidal compositions include one or more cationic steroidal antimicrobials (CSAs). The sporicidal compositions may be applied to an object to kill or deactivate bacterial spores contacting the sporicidal composition. The object may be a food product, food processing equipment, industrial equipment, or healthcare facility objects. The sporicidal composition may be administered to a subject that has, is suspected to have, or is at risk for an infection associated with spore-forming bacteria.

Use of cationic steroidal antimicrobials for sporicidal activity

A system and method for programmably operating a DC load connected to a DC outlet. A power line communication (PLC) client at the outlet measures actual and desired DC voltage at the load. A remotely located DC power server is connected between a DC power source and the outlet. The power server has a PLC master in bidirectional feedback communication with the PLC client to determine the actual and desired DC voltage at the load. An adjustable DC voltage module at the power server is controlled by the PLC master to supply an adjustable DC voltage. The power server adjusts the DC voltage supplied by the voltage module to the load based on the bidirectional feedback communication between the PLC master and the PLC client.

System and method for programmably operating DC loads

A hydrogel polymer includes a ceragenin compound. The ceragenin compound has a hydrophobicity/hydrophilicity that produces a release rate in a range of 0.1-100 &#x3bc;g/ml for at least 3 days.

Hydrogel materials incorporating eluting ceragenin compound

Disclosed herein are cationic steroidal antimicrobials ('CSAs' or 'ceragenins') and methods of making the same. Particularly advantageous methods are identified for the synthesis of CSAs. CSAs may be formulated for treating subjects with ailments responsive to CSAs, including but not limited to treating bacterial infections. Accordingly, some embodiments include formulations and methods of administering CSAs.

Cationic steroidal antimicrobial compounds

Methods of treating, reducing, or preventing a disease or symptom relating to a disease such as oral mucositis, gingivitis, periodontitis, gastric mucositis, inflammatory fibrosis, gastritis, colitis, ileitis, Crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, ulcerative colitis, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer, a gastrointestinal ulcer, an autoimmune disorder, inflammation associated with cancer, cancer treatment, or radiation, and/or pain that include: identifying a patient in need of treatment; and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.

Growing community of inventors

Mapleton, UT, United States of America

Paul B Savage